- alopecia areata - myasthenia gravis and alopecia areata
(Jul. 2005). Patients affected with myasthenia gravis
often have autoimmune skin disorders and they are seen to
be affected by alopecia areata too. Hence, a study to understand
the relationship between myasthenia gravis and alopecia areata
was conducted on Japanese myasthenia gravis patients.
- alopecia areata - drug AS-101 as a candidate treatment for alopecia
areata (Jul. 2005). AS-101 is an immunomodulatory drug and
a hair growth promoter. In this study, the drug was tested for
its immuno suppressive effects on the inflammatory activity
of blood cells from children
who have patchy alopecia areata.
- alopecia areata - macrophage migration inhibition factor
gene sequences are a strong risk factor for early onset of
extensive alopecia areata (Jun. 2005). It is evident to
a certain extent that cytokines (chemical signals that cells
make and use to communicate with other cells) and certain
enzymatic discrepancies play important roles in the pathogenesis
of alopecia areata. This study suggests macrophage migration
inhibition factor may help determine susceptibility to alopecia
- alopecia areata - oxidant/antioxidant status in alopecia
areata (Jun. 2005). Since alopecia areata is considered
an autoimmune disease mediated by T lymphocytes, an analysis
of the role played by lipid peroxidation and antioxidant enzymes
in patients with alopecia areata was conducted.
- alopecia areata - thyroid autoimmunity in children with
alopecia areata (Jun. 2005).
Alopecia areata can be associated with the development
of other autoimmune disorders including thyroid autoimmunity. In this study,
children with alopecia areata were checked for the presence
of thyroid autoimmune disease.
- alopecia areata - congenital alopecia areata (Feb. 2005).
Alopecia areata is a non-scarring hair loss disease that can
occur in any stage of our life. In most cases the condition
occurs sometime after birth. This study however examines the
prevalence of alopecia areata in infants as a congenital condition
- in other words, when the alopecia areata is present from
- alopecia areata - pulse prednisolone therapy in alopecia
areata (Feb. 2005). Considered to be an autoimmune disease,
alopecia areata is often treated with systemic corticosteroids.
This study examines oral pulse therapy using prednisolone,
a glucocorticoid used to treat many different inflammatory
conditions, in a group of patients with severe alopecia areata.
- alopecia areata - diphencyprone treatment returns alopecia
areata patients' immune system to a more normal state (Jul.
2004). Diphenylcyclopropenone or Diphencyprone is the
most effective treatment available so far for treating extensive
alopecia areata (but not available in the USA). In this study,
the peripheral blood mononuclear cells were examined to find
out what changes occur in the lymphocyte cells as a result
of DCP treatment.
- alopecia areata - apoptosis resistance in peripheral blood
lymphocytes of alopecia areata patients (Jul. 2004). Studies
involving peripheral blood mononuclear cells have revealed
significant changes in patients with alopecia areata in comparison
with normal individuals. This report indicates T-cell activation
and increases in the blood levels of CD16 positive cells and
cytokine signaling chemical Tumor necrosis factor-alpha in
patients with alopecia areata.
- alopecia areata - what actually happens to the hair when
an individual is affected by alopecia areata (Jun. 2004).
Most of the earlier histopathological studies on the deterioration
of hair follicles in alopecia areata patients were conducted
on scalp tissues of already bald or severely affected individuals.
In this study, the early stages of hair follicle modifications
in alopecia areata were studied.
- alopecia areata - biological responses to diphencyprone
treatment (May. 2004). Diphencyprone is a potent contact
allergen which is used as an immunotherapeutic in treating
is focused on the effectiveness of this treatment and how the
hair follicles behave to the immunotherapy.
- alopecia areata - national registry established for
alopecia areata (21 Feb. 2001). A national DNA repository
was developed in the USA funded by the National Institutes
- alopecia areata - conference report (5 Nov. 1998).
This is a report from the third international workshop on
held in Washington DC.